Compositions and Methods for Treating Hypertension by Modulating Endocrine Activity
Disclosed herein are compounds and ligands, and antihypertensive compositions formed therewith, that modulate seminal endocrine factors that control blood pressure and, thereby, treat hypertension. Also disclosed herein are methods for using the antihypertensive compositions to treat hypertension and disorders associated therewith.
1 . A composition for treating hypertension and hypertension associated disorders of a patient, comprising:
an antihypertensive composition comprising a delivery medium, propionic acid and 3-methylpentanoic acid, said propionic acid comprising an EC 50 value in the range of from about 0.05 μM to about 0.5 μM, said 3-methylpentanoic acid comprising an EC 50 value in the range of from about 5.0 μM to about 50.0 μM,
said antihypertensive composition adapted to induce at least serotonin (5-HT), secretin, prostaglandin E 2 and vasoactive intestinal protein secretion in vivo, whereby, when said antihypertensive composition is delivered to said patient, vasodilation of said patient is induced.
2 . The composition of claim 1 , wherein said EC 50 value of said propionic acid in said antihypertensive composition is in the range of from about 0.1 μM to about 0.2 μM.
3 . The composition of claim 1 , wherein said EC 50 value of said 3-methylpentanoic acid in said antihypertensive composition is in the range of from about 10.0 μM to about 30.0 μM.
4 . The composition of claim 1 , wherein said antihypertensive composition further comprises butyrate.
5 . The composition of claim 4 , wherein said butyrate comprises an EC 50 value in said antihypertensive composition in the range of from about 0.01 μM to about 0.3 μM.
6 . The composition of claim 1 , wherein said antihypertensive composition is sufficient to induce at least 50% activation of at least one ectopic olfactory receptor selected from the group consisting of olfactory receptor OR51E1, olfactory receptor OR51E2, free fatty acid receptor FFAR2 and free fatty acid receptor FFAR3 in vivo when the antihypertensive composition is delivered to a patient.